Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

Launched by MASSACHUSETTS GENERAL HOSPITAL · Mar 11, 2020

Keywords

ClinConnect Summary

To date, no targeted therapeutic treatments for the ongoing COVID-19 outbreak have been identified. Antiviral combined with adjuvant therapies are currently under investigation. The clinical spectrum of the infection is wide, ranging from mild signs of upper respiratory tract infection to severe pneumonia and death.

In the patients who progress, the time period from symptoms onset to development of dyspnea is reported to be between 5 to 10 days, and that one to severe respiratory distress syndrome from 10 to 14 days. Globally, 15 to 18% of patients deteriorates to the need of mechanical ve...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Laboratory confirmed COVID19 infection defined with a positive RT-PCR from any specimen and/or detection of SARS-CoV-2 IgM/IgG antibodies.
• 2. Hospital admission with at least one of the following:
• • 1. fever ≥ 36.6 °C from axillary site; or ≥ 37.2°C from oral site; or ≥ 37.6°C from tympanic or rectal site.
• • 2. Respiratory rate ≥ 24 bpm
• • 3. cough
• • 3. Spontaneous breathing with or without hypoxia of any degree. Gas exchange and ventilation maybe assisted by any continuous continuous airway pressure (CPAP), or any system of Non Invasive Ventilation (NIV), with Positive End-Expiratory Pressure (PEEP) ≤ 10 cmH2O.
• Exclusion Criteria:
• • 1. Tracheostomy
• • 2. Therapy with high flow nasal cannula
• • 3. Any clinical contraindications, as judged by the attending physician
• • 4. Patients enrolled in another interventional study
• • 5. Hospitalized and confirmed diagnosis of COVID-19 for more than 72 hours
• • 6. Previous intubation for COVID-19
• • 7. Patient not committed to full support (DNR, DNI or CMO)
• • 8. Patient requiring oxygen at home for lung comorbidities
• • 9. Primary cause of hopitalization not due to COVID-19